The comparison of Hepatitis B vaccination in two methods, routine and accelerated

A Comparison of protective antibody level two years after accelerated and conventional vaccination against hepatitis B infection

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

IRCT

Registry ID

IRCT201110287341N2

Enrollment

160

Registered

2011-11-03

Start date

2008-07-15

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hepatitis B. Acute hepatitis B

Interventions

Intervention 1: routin Hepatitis B vaccination method (Hepatobax Belgian vaccine, in months of 0, 1, 6. with dose of 20 micrograms in Deltoid mascle). Intervention 2: accelerated Hepatitis B vaccinat

Prevention

routin Hepatitis B vaccination method (Hepatobax Belgian vaccine, in months of 0, 1, 6. with dose of 20 micrograms in Deltoid mascle)

accelerated Hepatitis B vaccination method (Hepatobax Belgian vaccine, in days of 0, 10, 21. with dose of 20 micrograms in Deltoid mascle)

Eligibility

Sex/Gender

All

Age

No minimum to 50 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: age<50 years old; No history of vaccination or infection with hepatitis B, No history of liver or kidney failure; No history of HIV infection and long-term use of immunosuppressant drugs. Exclusion criteria: HBS Ag or HBS Ab positive persons.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Hepatitis B Antibody titer. Timepoint: 2 years after vaccination. Method of measurement: ELISA method.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Siavash Vaziri

Kermanshah University of medical sciences and health services

daneshjoo_entekhab@yahoo.com+98 42763016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026